Cyclosporine treatment of glomerular diseases

Annual Review of Medicine

Volumn 50, Issue , 1999, Pages 1-15

  Klein, Michael ^a   Radhakrishnan, Jai ^a   Appel, Gerald ^a  

^a Howard Hughes Medical Institute   (United States)

Author keywords

Cyclosporine; Glomerular disease treatment; Nephrotic syndrome; Toxicity

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; STEROID;

DRUG EFFICACY; DRUG TOXICITY; FOCAL GLOMERULOSCLEROSIS; GINGIVA HYPERPLASIA; GLOMERULOPATHY; HIRSUTISM; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPERURICEMIA; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY FAILURE; LUPUS ERYTHEMATOSUS NEPHRITIS; LUPUS VULGARIS; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MEMBRANOUS GLOMERULONEPHRITIS; MINIMAL CHANGE GLOMERULONEPHRITIS; NEPHROTOXICITY; NEUROTOXICITY; PRIORITY JOURNAL; RELAPSE; REVIEW;

AUTOIMMUNE DISEASES; AZATHIOPRINE; CYCLOSPORINE; DRUG COMBINATIONS; GLOMERULONEPHRITIS; GLOMERULONEPHRITIS, IGA; GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE; GLOMERULONEPHRITIS, MEMBRANOUS; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; LUPUS NEPHRITIS; NEPHROTIC SYNDROME; RECURRENCE; STEROIDS;

EID: 0032977927     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.50.1.1     Document Type: Review

References (72)

1. 1. von Graffenreid B, Friend D, Shand N, et al. 1989. Cyclosporin A (Sandimmun®) in autoimmune disorders. In Cyclosporin: Mode of Action and Clinical Application, ed. AW Thomson, pp. 213-51. Dordrecht: Kluwer
2. 2. Ambalavanan S, Fauvel JP, Sibley RK, Myers BD. 1996. Mechanism of the antiproteinuric effect of cyclosporine in membranous nephropathy. J. Am. Soc. Nephrol. 7:290-98
3. 3. Wiegmann TB, Sharma R, Diedrich DA, Savin VJ. 1990. In vitro effects of cyclosporine on glomerular function. Am. J. Med. Sci. 299(3): 149-52
4. 4. Savin VJ. 1993. Mechanisms of proteinuria in noninflammatory glomerular diseases. Am. J. Kidney Dis. 21:347-62
5. 5. Tejani AT, Butt K, Trachtman H, et al. 1988. Cyclosporine A induced remission of relapsing nephrotic syndrome in children. Kidney Int. 33: 729-34
6. 6. Tejani A, Suthanthiran M, Pomrantz A. 1991. A randomized controlled trial of low-dose prednisone and ciclosporin versus high-dose prednisone in nephrotic syndrome of children. Nephron 59:96-99
7. 7. Cattran D, Greenwood C, Bernstein K, et al. 1995. Results of a 6 month randomized controlled trial of cyclosporine (T) vs placebo (c) in adults with steroid resistant idiopathic focal segmental glomerulosclerosis (SR-FSGS). J. Am. Soc. Nephrol. 6:415 (Abstr.)
8. 8. Capodicasa G, De Santo NG, Nuzzi F. 1986. Cyclosporine A in nephrotic syndrome of childhood-a 14 month experience. Int. J. Pediatr. Nephrol. 7:69-72
9. 9. Garin EH, Orak JK, Hiott KL. 1988. Cyclosporine therapy for steroid-resistant nephrotic syndrome. Am. J. Dis. Child. 142: 985-88
10. 10. Ponticelli C, Rizzoni G, Edefonti A, et al. 1993. A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome. Kidney Int. 43:1377-84
11. 10a. Niaudet P. 1994. Treatment of childhood steroid-resistant idiopathic nephrosis with a combination of cyclosporine and prednisone. French Society of Pediatric Nephrology. J. Pediatr. 125:981-86
12. 11. Niaudet P. 1992. Comparison of cyclosporin and chlorambucil in the treatment of steroid-dependent idiopathic nephrotic syndrome: a multicentre randomized controlled trial. Pediatr. Nephrol. 6:1-3
13. 12. DeSanto NG, Capodicasa G, Giordano C. 1989. Treatment of idiopathic membranous nephropathy unresponsive to methylprednisolone and chlorambucil with cyclosporine. Am. J. Nephrol. 7: 74-76
14. 13. Cattran DC, Greenwood C, Ritchie S, et al. 1995. A controlled trial of cyclosporin in patients with progressive membranous nephropathy. Kidney Int. 47:1130-35
15. 13a. Cattran DC, Pohl M, Maxwell D, et al, for North American Nephrotic Syndrome Study Group. 1998. Randomized controlled trial of cyclosporine (D) vs placebo (P) in steroid resistant, nephrotic patients (NS) with membranous nephropathy (SR-MGN). J. Am. Soc. Nephrol. (Abstr.) In press
16. 14. Erbay B, Karatan O, Duman N, Ertug AE. 1988. The effect of cyclosporine in idiopathic nephrotic syndrome resistant to immunosuppressive therapy. Transplant Proc. 20:292 (Suppl. 4)
17. 15. Rostoker G, Maadi AB, Sandreux T. 1997. Long term cyclosporin A therapy for severe idiopathic membranous nephropathy. Nephron 63:335-41
18. 16. Ponticelli C, Edefonti A, Ghio L, et al. 1993. Cyclosporin versus cyclophosphamide for patients with steroid-dependent and frequently relapsing idiopathic nephrotic syndrome: a multicenter randomized controlled trial. Nephrol. Dial. Transplant. 8:1326-32
19. 17. Ingulli E, Tejani A. 1992. Severe hypercholesterolemia inhibits cyclosporine A efficacy in a dose-dependent manner in children with nephrotic syndrome. J. Am. Soc. Nephrol. 3:254-59
20. 18. Ponticelli C, Zuchelli P, Imbasciati E, et al. 1984. Controlled trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N. Engl. J. Med. 310:946-50
21. 19. Meyrier A, Noel L, Auriche P, Callard P. 1994. Long-term renal tolerance of cyclosporin A treatment in adult idiopathic nephrotic syndrome. Collaborative Group of the Societé de Nephrologie. Kidney Int. 45:1446-56
22. 20. Ponticelli C, Passerini P. 1997. Treatment of the nephrotic syndrome associated with primary glomerulonephritis. Kidney Int. 46:595-604
23. 21. Korbet SM, Schwartz MM, Lewis EJ. 1994. Primary focal segmental glomerulosclerosis: clinical course and response to therapy. Am. J. Kidney Dis. 23:773-83
24. 22. Deleted in proof
25. 23. Cattran D, Greenwood C, Hebert L, et al. 1995. Follow up results from a randomized controlled trial (RCT) of cyclosporine (T) vs placebo (C) in adults with steroid resistant idiopathic focal segmental glomerulosclerosis (SR-FSGS). J. Am. Soc. Nephrol. 6:414 (Abstr.)
26. 24. Meyrier A, Condamin MC, Broneer D, Collaborative Group of the French Society of Nephrology. 1991. Treatment of adult idiopathic nephrotic syndrome with cyclosporin A: minimal-change disease and focal-segmental glomerulosclerosis. Clin. Nephrol. 35:37-42 (Suppl. 1)
27. 25. Niaudet P, Broyer M, Habib R. 1991. Treatment of idiopathic nephrotic syndrome with cyclosporin A in children. Clin. Nephrol. 35:531-36 (Suppl. 1)
28. 26. Ponticelli C, Zucchelli P. 1995. A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int. 48:1600-4
29. 27. Schiepatti MD, Mosconi L, Perna A, et al. Prognosis of untreated patients with idiopathic membranous nephropathy. N. Engl. J. Med. 1993;329:85-89
30. 28. Hogan SL, Muller KE, Jennette JC, Falk RJ. 1995. A review of therapeutic studies of idiopathic membranous glomerulopathy. Am. J. Kidney Dis. 25:862-75
31. 29. Imperiale TF, Goldfarb S, Berns JS. 1995. Are cytotoxic agents beneficial in idiopathic membranous nephropathy? A meta-analysis of the controlled trials. J. Am. Soc. Nephrol. 5:1543-45
32. 30. Guasch A, Suranyi M, Newton L, et al. 1992. Short-term responsiveness of membranous glomerulopathy to cyclosporine. Am. J. Kidney Dis. 20:472-81
33. 31. D'Amico G. 1987. The commonest glomerulonephritis in the world: IgA nephropathy. Q. J. Med. 64:709-27
34. 32. Berg UB. 1991. Long term follow up of renal function in IgA nephropathy. Arch. Dis. Child 66:588-92
35. 33. DeCaestecker MP, Bottomley M, Telfer BA. 1993. Detection of abnormal peripheral blood mononuclear cell cytokine networks in human IgA nephropathy. Kidney Int. 44:1298-308
36. 34. Schena FP, Gesualdo L, Montinaro V. 1992. Immunopathological aspects of immunoglobulin A nephropathy and other mesangial proliferative glomerulonephritides. J. Am. Soc. Nephrol. 2:167-82
37. 35. Donadio JVJ. 1991. Omega-3 polyunsaturated fatty acids: a potential new treatment of immune renal disease. Mayo Clin. Proc. 66:1018
38. 36. Kobayashi Y, Fujii K, Hiki Y, et al. 1986. Steroid therapy in IgA nephropathy: a prospective pilot study in moderate proteinuric cases. Q. J. Med. 61:935-43
39. 37. Bennett WM, Walker RG, Kincaid-Smith PS. 1989. Treatment of IgA nephropathy with eicosapentanoic acid (EPA): a two-year prospective trial. Clin. Nephrol. 31: 128-31
40. 38. Lai KN, Lai M, Vallance-Own J. 1988. A short-term controlled trial of cyclosporine-A in IgA nephropathy. Transplant Proc. 20:297-303
41. 39. Valeri A, Radhakrishnan J, Estes D, et al. 1994. Intravenous cyclophosphamide treatment of severe lupus nephritis: a prospective five year study. Clin. Nephrol. 42:71-78
42. 40. Boumpas DT, Austin HAI, Vaughn EM, et al. 1992. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 340:741-45
43. 41. Gourley MF, Austin HA III, Scott D, et al. 1997. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann. Intern. Med. 125:549-57
44. 42. Bansal VK, Beto JA. 1997. Treatment of lupus nephritis: a meta-analyses of clincal trials. Am. J. Kidney Dis. 29:193-99
45. 43. Israel-Biet D, Noel LH, Bach MA, et al. 1983. Marked reduction of DNA antibody production and glomerulopathy in thymulin (FTS-Zn) of cyclosporin A treated (NZB X NZW) F1 mice. Clin. Exp. Immunol. 54:359
46. 44. Jones MG, Harris G, Cowing G. 1983. Response of murine autoimmune disease to cyclosporine and thiols. Transplant Proc. 15:2904 (Suppl. 1)
47. 45. Jones MG, Harris G. 1985. Prolongation of life in female (NZB/NZW)F1 hybrid mice by cyclosporin-A. Clin. Exp. Immunol. 59:1-9
48. 46. Gunn HC. 1986. Successful treatment of autoimmunity in (NZBxNZW)F1 mice with cyclosporin and (Nva2)-cyclosporin. I. Reduction of autoantibodies. Clin. Exp. Immunol. 64:225-33
49. 47. Appleby P, Webber DG, Bowen JG. 1989. Murine chronic graft-versus-host disease as a model of systemic lupus erythematosus: effect of immunosuppressive drugs on disease development. Clin. Exp. Immunol. 78:449-53
50. 48. Miescher PA, Favre H, Mihatsch MJ, et al. 1994. The place of cyclosporine A in the treatment of connective tissue diseases. Transplant Proc. 20:224-37 (Suppl. 4)
51. 49. Miescher PA, Miescher A. 1985. Combined cyclosporine-steroid treatment of systemic-lupus erythematosus. In Cyclosporin in Autoimmune Disease, ed. R Schindler, pp. 337-45. Berlin: Springer-Verlag
52. 50. Favre H, Miescher A, Huang YP, et al. 1989. Ciclosporin in the treatment of lupus nephritis. Am. J. Nephrol. 9:57-60 (Suppl.)
53. 51. Feutren G, Querin S, Noel LH, et al. 1987. Effects of cyclosporine in severe systemic lupus erythematosus. J. Pediatr. 111: 1063-68
54. 52. Tokuda M, Kurata N, Mizoguchi A, et al. 1994. Effect of low-dose cyclosporin A on systemic lupus erythematosus disease activity. Arthritis Rheum. 37:551-58
55. 53. Enriquez R, Tovar JV, Amoros F, et al. 1991. Can ciclosporin be used without steroids in systemic lupus erythematosus? Nephron 57:367-68
56. 54. Hussein MM, Mooij JM, Roujouleh H. 1993. Cyclosporine in the treatment of lupus nephritis including two patients treated during pregnancy. Clin. Nephrol. 40:160-63
57. 55. LeFrancois N, Deteix P, Laville M, Zech P. 1984. Treatment of systemic lupus with cyclosporin A: a patient with a 1-year follow-up. Kidney Int. 26:225
58. 56. Favre H, Miescher PA, Lemoine R. 1994. Use of cyclosporine in the treatment of autoimmune disorders. Transplant Proc. 26:3194-96
59. 57. Radhakrishnan J, Szabolcs M, D'Agati V, et al. 1993. Lupus membranous nephropathy(LMN): course and prognosis in 50 patients. J. Am. Soc. Nephrol. 4:284 (Abstr.)
60. 58. Baldwin DS, Gluck MC, Lowenstein J, Gallo GR. 1977. Lupus nephritis: clinical course as related to morphologic forms and their transitions. Am. J. Med. 62: 12-30 (Abstr.)
61. 59. Appel GB, Cohen DJ, Pirani CL, et al. 1987. Long-term follow-up of patients with lupus nephritis. Am. J. Med. 83: 877-85
62. 60. Donadio JVJ. 1992. Treatment of membranous nephropathy in systemic lupus erythematosus. Nephrol. Dial. Transplant. 7:97-104 (Suppl. 1)
63. 61. Appel GB, Silva FG, Pirani CL, et al. 1978. Renal involvement in systemic lupus erythematosus (SLE): a study of 56 patients emphasizing histologie classification. Medicine 57(5):371-410
64. 62. Ponticelli C, Rivolta E. 1988. Cyclosporine in nephrotic syndrome. Transplant Proc. 20:253-58
65. 63. Lewis EJ, Hunsicker LG, Lan SP, et al. 1992. A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. N. Engl. J. Med. 326:425-27
66. 64. Radhakrishnan J, Kunis CL, D'Agati V, Appel GB. 1994. Cyclosporine treatment of lupus membranous nephropathy. Clin. Nephrol. 42:147-54
67. 65. Schollmeyer P, Grotz W. 1990. Ciclosporin in the treatment of Wegener's granulomatosis (WG) and related diseases. APMIS Suppl. 19:54-55
68. 66. Borleffs JCC, Derksen RHWM, Hene RJ. 1988. Wegener's granulomatosis and cyclosporine. Transplant Proc. 20:344-45 (Suppl. 20)
69. 67. Harley N. Ihle B. 1990. Wegener's granulomatosis-use of cyclosporin-A: a case report. Aust. NZJ. Med. 20:71-73
70. 67a. Haubitz M, Koch KM, Brunkhorst R. 1997. Cyclosporine for the prevention of relapses in ANCA-associated vasculitis. J. Am. Soc. Nephrol 8:86A (Abstr.)
71. 68. Hoyer PF. 1995. Complications of cyclosporin therapy. In Contributions to Nephrology: Cyclosporin in the Therapy of Renal Disease, ed. A Tejani, 114:111-23. Basel: Karger
72. 69. Feutren G, Mihatsch MJ. 1992. For the International Kidney Biopsy Registry of Cyclosporine in Autoimmune Disease. Risk factors for cyclosporine nephropathy in patients with autoimmune diseases. N. Engl. J. Med. 326:1654-60